Q1 2023 EPS Estimates for Oncolytics Biotech Inc. Decreased by Analyst (NASDAQ:ONCY)

Oncolytics Biotech Inc. (NASDAQ:ONCY – Get Rating) – Investment analysts at HC Wainwright dropped their Q1 2023 earnings per share estimates for Oncolytics Biotech in a research report issued to clients and investors on Tuesday, March 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.07) for the quarter, down from their prior forecast of ($0.05). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2023 earnings at ($0.07) EPS, Q3 2023 earnings at ($0.06) EPS, Q4 2023 earnings at ($0.06) EPS, FY2023 earnings at ($0.26) EPS, FY2024 earnings at ($0.23) EPS and FY2025 earnings at ($0.20) EPS.

ONCY has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oncolytics Biotech in a research note on Monday, March 6th. Canaccord Genuity Group dropped their target price on shares of Oncolytics Biotech from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, March 6th.

Oncolytics Biotech Stock Performance

Shares of NASDAQ ONCY opened at $1.43 on Thursday. The stock’s 50-day simple moving average is $1.65 and its 200-day simple moving average is $1.53. The firm has a market capitalization of $88.13 million, a PE ratio of -4.47 and a beta of 2.15. Oncolytics Biotech has a fifty-two week low of $0.80 and a fifty-two week high of $2.28.

Institutional Trading of Oncolytics Biotech

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in Oncolytics Biotech by 75.7% in the third quarter. Renaissance Technologies LLC now owns 24,600 shares of the company’s stock valued at $30,000 after buying an additional 10,600 shares during the last quarter. Newman Dignan & Sheerar Inc. raised its position in Oncolytics Biotech by 46.5% in the 4th quarter. Newman Dignan & Sheerar Inc. now owns 18,915 shares of the company’s stock valued at $31,000 after purchasing an additional 6,000 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Oncolytics Biotech during the 2nd quarter worth $34,000. Lynwood Capital Management Inc. acquired a new stake in Oncolytics Biotech during the 4th quarter worth $41,000. Finally, Virtu Financial LLC purchased a new stake in shares of Oncolytics Biotech in the fourth quarter valued at about $41,000. 1.20% of the stock is owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

(Get Rating)

Oncolytics Biotech, Inc engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses.